Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs

Annals of Allergy, Asthma and Immunology

Volumn 98, Issue 2, 2007, Pages 168-171

  Muratore, Lionello ^a   Ventura, Mariateresa ^a,b   Calogiuri, Gianfranco ^c   Calcagnile, Fabio ^c   Quarta, Eugenio ^c   Muratore, Maurizio ^c   Ferrannini, Antonio ^b  

^a VITO FAZZI HOSPITAL   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c Galateo Hospital San Cesario di Lecce   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; HEART RATE; HUMAN; MALE; PEAK EXPIRATORY FLOW; PRESCRIPTION; PRIORITY JOURNAL; PROVOCATION TEST; RASH; SINGLE BLIND PROCEDURE; URTICARIA;

EID: 33846846457     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60691-6     Document Type: Article

References (18)

1. Sainte-Laudy J, Vallon C. Nine cases of suspected IgE mediated anaphylaxis induced by aspirin. Allergy Clin Immunol Int. 2002;14:220-222.
2. Blanca M, Perez E, Garcia JJ, et al. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy. 1989;62:295-298.
3. Zhu DX, Zhao JL, Li M, Li HL. Identification and characterization of IgE reactivities to aspirin and related compounds. J Invest Allergol Clin Immunol. 1997;7:160-168.
4. Asero R. Intolerance to non-steroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol. 2003;111:1095-1098.
5. Asero R, Tedeschi A, Lorini M. Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs. Ann Allergy Asthma Immunol. 2002;88:468-472.
6. Hide M, Francis DM, Grattan CEH. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328:1599-1604.
7. Grattan CEH. Aspirin sensitivity and urticaria. Clin Exp Dermatol. 2003;28:123-127.
8. Kubota Y, Imayama S, Toshitani A. Sulfidoleukotriene release test (CAST) in hypersensitivity to non steroidal anti-inflammatory drugs. Int Arch Allergy Immunol. 1997;114:361-366.
9. Mastarlez R, Sekowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004;113:771-775.
10. FitzGerald GA, Patrono C. The coxibs: selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
11. Tacconelli S, Capone ML, Patrignani P. Clinical pharmacology of novel selective COX-2 inhibitors. Curr Pharm Des. 2004;10:589-601.
12. Rodrigues AD, Halpin RA, Geer LA, et al. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos. 2003;31:224-232.
13. Quiralte J, Saenz de San Pedro B, Florido JJ. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol. 2002;89:63-66.
14. Asero R. Tolerability of rofecoxib. Allergy. 2001;56:916-917.
15. Perrone MR, Artesani MC, Viola M, et al. Tolerability of rofecoxib in patients with adverse reaction to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol. 2003;132:82-86.
16. Liccardi G, Senna G, Russo M, et al. Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. J Investig Allergol Clin Immunol. 2004;14:104-107.
17. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patient with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol. 2005;95:154-158.
18. Kruse R, Ruzicka T, Grewe M. Intolerance reactions due to selective cyclooxygenases type 2 inhibitors rofecoxib and celecoxib. Acta Dermatol Venereol. 2003;83:183-185.